Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 17, 2019updated 23 Dec 2019 8:35am

Alnylam begins Phase III study of patisiran in ATTR amyloidosis

Alnylam Pharmaceuticals has launched the Phase III APOLLO-B clinical trial to evaluate its RNAi therapeutic patisiran in adults suffering from transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.

Alnylam Pharmaceuticals has launched the Phase III APOLLO-B clinical trial to evaluate its RNAi therapeutic patisiran in adults suffering from transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy.

Available under the brand name Onpattro, patisiran is designed to target and silence transthyretin (TTR) messenger RNA in order to block the generation of TTR in the liver and minimise its accumulation in the body.

The randomised, double-blind, placebo-controlled, multi-centre, global APOLLO-B trial will assess the drug’s safety and efficacy in around 300 participants. It will recruit patients with hereditary or wild-type amyloidosis.

A 0.3mg/kg dose of patisiran administered intravenously every three weeks will be compared to placebo over 24 months. Following 12 months of therapy, all participants will be given the drug in an open-label period.

The primary endpoint of the study is the change in the six-minute walk test (6-MWT) from baseline to 12 months.

APOLLO-B will also track the secondary endpoints of efficacy on quality of life measured with the Kansas City Cardiomyopathy Questionnaire Overall Summary and composite endpoints of mortality and hospitalisation.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Alnylam Pharmaceuticals TTR Program senior vice-president and general manager Eric Green said: “Based on the encouraging exploratory results on cardiac endpoints in the Phase III APOLLO study, we are investigating the potential for patisiran to treat cardiovascular-related manifestations of ATTR amyloidosis.

“The initiation of APOLLO-B represents a significant milestone in our commitment to explore the full potential of patisiran for patients living with all types of ATTR amyloidosis.”

The drug already has approvals in the US, Canada and Japan to treat hereditary ATTR amyloidosis (hATTR amyloidosis) with polyneuropathy in adults.

In addition, the European regulatory authority approved the drug for the treatment of hATTR amyloidosis in adults with stage I or II polyneuropathy.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU